191 completed, 99 unknown, 24 terminated, 10 withdrawn. 347 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 347 | Completed 191, Unknown 99, Terminated 24, Withdrawn 10, Active not recruiting 9, Not yet recruiting 8, Recruiting 6 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants Bepirovirsen - Hepatitis B | Phase 4 | Not yet recruiting | GlaxoSmithKline | 303 | 2026-12-03 | 2026-11-02 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach Tenofovir Alafenamide (TAF), Community-Based Support, Simplified WHO 2024 Criteria - Chronic Hepatitis B, Hepatitis B Virus Infection | Phase 4 | Not yet recruiting | The Task Force for Global Health | 6000 | 2026-01-01 | 2025-12-02 |
| Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B Peginterferon alfa-2b Injection - HBV, Chronic Hepatitis B Virus | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 113 | 2026-01-01 | 2025-11-17 |
| Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients Peg-IFN α-2b combined with NAs - Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B | Phase 4 | Not yet recruiting | Shenzhen Third People's Hospital | 830 | 2025-08-15 | 2025-07-17 |
| Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg PegIFN alfa-2b, PegIFN alfa-2b and NUC - Chronic Hepatitis B | Phase 4 | Not yet recruiting | Huashan Hospital | 360 | 2025-04-01 | 2025-03-28 |
| ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα - Chronic Hepatitis b | Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2024-05-21 | 2026-09-01 |
| SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus Dapagliflozin 10mg Tab, Placebo 10mg Tab - Chronic Hepatitis B | Phase 4 | Recruiting | Chinese University of Hong Kong | 412 | 2024-03-26 | 2026-03-18 |
| Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） Peg-Interferon α - Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 1500 | 2024-01-01 | 2024-04-16 |
| Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir Vemliver tablet, Baracross Tablet - Hepatitis B, Chronic | Phase 4 | Completed | Daewoong Pharmaceutical Co. LTD. | 196 | 2023-08-28 | 2025-03-18 |
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF Ergocalciferol Capsules, Calcium carbonate - Parathyroid Hormone, Tenofovir Disoproxil Fumarate | Phase 4 | Completed | Mahidol University | 64 | 2022-05-01 | 2024-09-05 |
| Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment Avatrombopag, Artificial Liver Support System, Comprehensive internal medical treatment. - Thrombocytopenia, Hepatitis B, Chronic | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 60 | 2022-04-27 | 2022-11-10 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB Tenofovir Amibufenamide（TMF） - Hepatitis B, Chronic | Phase 4 | Active not recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 640 | 2022-03-10 | 2024-12-19 |
| Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy Mycophenolate Mofetil, Tacrolimus - Autoimmune Hepatitis | Phase 4 | Unknown | Leiden University Medical Center | 86 | 2022-01-19 | 2022-02-03 |
| Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients Peginterferon Alfa-2B, Nucleoside Analogs - Hepatitis B, Chronic | Phase 4 | Recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 5000 | 2022-01-08 | 2025-05-01 |
| Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients Empagliflozin 10 MG, Placebo pills - Chronic Hepatitis b, NAFLD | Phase 4 | Active not recruiting | The University of Hong Kong | 106 | 2022-01-02 | 2026-01-30 |
| Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B Stop group - Hepatitis B, Chronic | Phase 4 | Completed | Asan Medical Center | 140 | 2021-09-01 | 2026-08-04 |
| Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels Treatment - Hepatitis B, Chronic | Phase 4 | Active not recruiting | Asan Medical Center | 600 | 2021-08-23 | 2024-10-09 |
Showing 20 of 347. Sign in to see all of them.
Hepatitis B, Chronic (190) · Hepatitis C, Chronic (144) · Hepatitis C (34) · Hepatitis B (31) · Fibrosis (9) · Liver Cirrhosis (9) · Hepatitis, Autoimmune (8) · Carcinoma, Hepatocellular (7) · HIV Infections (7) · Hepatitis (7) · Coinfection (4) · Insulin Resistance (4) · Kidney Failure, Chronic (4) · Opioid-Related Disorders (4)
Digestive System Diseases (347) · Liver Diseases (345) · Pathologic Processes (343) · Pathological Conditions, Signs and Symptoms (343) · Disease Attributes (340) · Hepatitis (340) · Chronic Disease (339) · Blood-Borne Infections (333) · Communicable Diseases (333) · Infections (333) · Hepatitis, Viral, Human (332) · Virus Diseases (332) · Hepadnaviridae Infections (191) · DNA Virus Infections (190)
peginterferon alfa-2a (104) · Ribavirin (86) · entecavir (51) · Tenofovir (35) · Lamivudine (27) · Telbivudine (24) · peginterferon alfa-2b (24) · adefovir dipivoxil (22) · adefovir (21) · tenofovir alafenamide (15) · Sofosbuvir (11) · sofosbuvir-velpatasvir drug combination (10) · clevudine (8) · Emtricitabine (6) · Mycophenolic Acid (4)
Hoffmann-La Roche (44) · Third Affiliated Hospital, Sun Yat-Sen University (13) · National Taiwan University Hospital (12) · Nanfang Hospital, Southern Medical University (10) · GlaxoSmithKline (9) · Bukwang Pharmaceutical (7) · Kaohsiung Medical University Chung-Ho Memorial Hospital (7) · Merck Sharp & Dohme LLC (7) · Yonsei University (7) · Novartis Pharmaceuticals (6) · Asan Medical Center (5) · Asian-Pacific Alliance of Liver Disease, Beijing (5) · Beijing Ditan Hospital (5) · Kirby Institute (5) · Korea University (5)
China (76) · South Korea (54) · United States (45) · Taiwan (38) · Germany (17) · Spain (14) · Canada (13) · Brazil (12) · Australia (11) · Hong Kong (11) · Italy (9) · France (8) · Netherlands (8) · Russia (7) · Sweden (7)
Chen-Hua Liu, MD (6) · Jun Cheng, M.D. (5) · Ming-Lung Yu, MD, PhD (5) · Cheng-Chao Liang, MD (4) · Chih-Lin Lin, MD (4) · Ching-Sheng Hsu, MD (4) · Jia-Horng Kao, MD, PhD (4) · Shih-Jer Hsu, MD (4) · Ding-Shinn Chen, MD (3) · Jee-Fu Huang, MD (3) · Jinlin Hou, MD (3)
PMID 24915612, PMID 25348661, PMID 28404091, PMID 28404092, PMID 15470215, PMID 19187608, PMID 20049753, PMID 21182232, PMID 22045673, PMID 22436845, PMID 23046671, PMID 23518903, PMID 24954675, PMID 25190434, PMID 26453773, PMID 26867206, PMID 28427875, PMID 29405329, PMID 30552056, PMID 30689258, PMID 35599306, PMID 37096802, PMID 40390028, PMID 10051494, PMID 11850253, PMID 12019083, PMID 12606735, PMID 12865912, PMID 14697813, PMID 15014185, PMID 15749627, PMID 15987917, PMID 16391218, PMID 16525137, PMID 16530509, PMID 16673294, PMID 17239478, PMID 17625124, PMID 17875007, PMID 17935165, PMID 17943989, PMID 18081737, PMID 18092326, PMID 18094378, PMID 18508296, PMID 18563054, PMID 18684176, PMID 18834319, PMID 19027013, PMID 19052126
2005 (4), 2004 (2), 2009 (1), 2015 (1), R01DA013806 (1)